Rajendran S D, Rao Y Madhusudan, Karthikeyan V P
Department of Pharmacy Practice, JSS College of Pharmacy, Ootacamund, India.
Indian J Med Res. 2005 Dec;122(6):511-7.
BACKGROUND & OBJECTIVE: Aminoglycoside antibiotics, especially gentamicin, are widely used in suspected Gram-negative infections in India. Therapeutic drug monitoring is not commonly used for this drug in our population. We evaluated the target concentration intervention (TCI) strategy of gentamicin therapy in a predominantly malnourished patient population with lower respiratory tract infection in south India.
Patients who were prescribed gentamicin for suspected lower respiratory tract infection were randomized to any of the three groups, viz., control (CG), once daily dosing (ODD), and pharmacokinetic dosing (TCI) groups. Diagnosis was initially done by clinical evaluation and confirmed radiologically. Patients in CG received 80 mg gentamycin twice daily, ODD group received 160 mg once daily, and TCI groups received 160 mg once daily initially followed by dose revision based on serum drug levels. Blood samples were collected at peak and trough levels and assayed for gentamicin concentration. Dose adjustment was done in TCI group whereas the other groups received standard doses. Efficacy and safety were evaluated as outcome measures.
Of the 52 patients included initially in the study, 43 (CG 20, ODD 12, TCI 11) completed the study. The doses administered to the study subjects were less than those prescribed in standard textbooks and guidelines. Patients in TCI group had their gentamicin doses revised upwardly to a dose of 4.3+/-0.6 mg/kg to achieve a peak gentamicin concentration of 12 to 15 microg/ml. Both ODD and TCI groups showed significant improvements in outcomes studied over the control group.
INTERPRETATION & CONCLUSION: The results of our study indicated that once daily dosing of gentamycin was superior to multiple daily dosing in treating the lower respiratory tract infection in the study population. All patients in the ODD and TCI groups achieved satisfactory serum drug concentrations at administered doses (160 mg/day for ODD and <or= 200 mg/day for TCI group). In our study, target concentration intervention did not significantly improve the therapy outcomes. Since the study sample is small further research may be needed.
氨基糖苷类抗生素,尤其是庆大霉素,在印度被广泛用于疑似革兰氏阴性菌感染的治疗。在我国人群中,该药的治疗药物监测并不常用。我们评估了庆大霉素治疗在印度南部以营养不良为主的下呼吸道感染患者群体中的目标浓度干预(TCI)策略。
因疑似下呼吸道感染而开具庆大霉素处方的患者被随机分为三组,即对照组(CG)、每日一次给药组(ODD)和药代动力学给药组(TCI)。最初通过临床评估进行诊断,并经影像学确认。CG组患者每日两次接受80mg庆大霉素,ODD组患者每日一次接受160mg,TCI组患者最初每日一次接受160mg,随后根据血清药物水平调整剂量。在血药浓度峰值和谷值时采集血样,检测庆大霉素浓度。TCI组进行剂量调整,而其他组接受标准剂量。以疗效和安全性作为观察指标进行评估。
最初纳入研究的52例患者中,43例(CG组20例、ODD组12例、TCI组11例)完成了研究。给予研究对象的剂量低于标准教科书和指南中规定的剂量。TCI组患者的庆大霉素剂量上调至4.3±0.6mg/kg以达到庆大霉素峰值浓度12至15μg/ml。ODD组和TCI组在研究的观察指标方面均显示出相对于对照组的显著改善。
我们的研究结果表明,在治疗研究人群的下呼吸道感染方面,庆大霉素每日一次给药优于每日多次给药。ODD组和TCI组的所有患者在给药剂量(ODD组为160mg/天,TCI组为≤200mg/天)下均达到了满意的血清药物浓度。在我们的研究中,目标浓度干预并未显著改善治疗效果。由于研究样本较小,可能需要进一步研究。